Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Novel Treatments and the Underlying Mechanisms for Diabetic Foot and Related Diseases
Diabetic foot is a serious complication of diabetes worldwide. The etiology of diabetic foot is quite complex due to its multifactorial nature. Diabetic neuropathy, peripheral artery disease, foot deformity, high blood glucose and secondary infection all can contribute to diabetic foot ulceration and gangrene, sometimes resulting in minor or major amputations. Several risk factors including old age, long-term diabetes, smoking, foot deformity, and ischemia have been identified in diabetic foot. Many diagnostic methods are used for early-stage diabetic neuropathy and peripheral arterial disease, such as pulse wave, ankle-brachial artery ratio, Sudoscan, gait analysis, etc. Due to the high glucose environment, metabolic disorder, ischemia and peripheral neuropathy, diabetic foot ulcer is much more difficult to heal than common traumatic wounds. Therefore, in addition to existing treatments, new methods or techniques are still needed to improve wound healing. We also expect to find novel pathways to elucidate the complicated mechanisms involved in diabetic foot and diabetic wound healing.
MicroRNA in Regenerative Medicine
Regulating virtually all biological processes, the genome's 2,654 newly discovered variants of mature microRNAs – short ribonucleic acid molecules found in eukaryotic cells – hold a key role in the body's toolkit of regenerative and reparative capacities. Identifying how to activate and deliver these specialist molecules may aid in the repair and regeneration of major tissue and organ damage in future therapies. In MicroRNA and Regenerative Medicine, Second Edition, over 50 leading experts address foundational and emerging topics in the field. Concisely summarizing and evaluating key findings from new research and their translational application, contributors examine current and future s...
Directory of Members
None
Who’s Who in Fluorescence 2004
The Who's Who in Fluorescence 2003 volume was published in November 2002. It featured some 312 personal entries from fluorescence workers all over the world. Initially we were unsure how useful the volume would be. However, it wasn't very long before we were inundated with requests for both bulk and personal orders. In addition a significant number of copies were freely distributed at conference venues, such as at the Biophysical Society meeting in San Antonio. Texas, March 2003, and at the Methods and Applications of Fluorescence Spectroscopy conference (MAFS) in Prague, Czech Republic, August 2003, where these two venues probably host the largest gathering of Fluorescence workers anywhere....
Circulation
None
Who’s Who in Fluorescence 2003
The Journal of Fluorescence's first Who's Who directory is to publish the names, contact details, specialty keywords and a brief description of scientists employing fluorescence methodology and instrumentation in their working lives. In addition the directory will provide company contact details with a brief list of fluorescence related products. Nothing like this has been published before for the Fluorescence field.
Chemoinformatics Approaches to Structure- and Ligand-Based Drug Design
Chemoinformatics is paramount to current drug discovery. Structure- and ligand-based drug design strategies have been used to uncover hidden patterns in large amounts of data, and to disclose the molecular aspects underlying ligand-receptor interactions. This Research Topic aims to share with a broad audience the most recent trends in the use of chemoinformatics in drug design. To that end, experts in all areas of drug discovery have made their knowledge available through a series of articles that report state-of-the-art approaches. Readers are provided with outstanding contributions focusing on a wide variety of topics which will be of great value to those interested in the many different and exciting facets of drug design.
